Frank Diamond

Managing Editor

Steve Jobs famously staked his claim at the intersection of technology and creativity. Health insurers are looking for the intersection of technology and benefits knowledge, but are not quite sure how to get there. Do you hire information technicians and train them in the ways of health coverage, or do you hire (or promote from within) people who know insurance and train them to be IT savvy? It’s a pressing question given that the government anticipates a shortage of about 50,000 qualified health information technology (HIT) workers between 2010 and 2015, according to the PwC study “Solving the Talent Equation for Health IT” .

“Across the health sector, senior executives describe a challenging paradox: just as they are preparing to make major increases in technology investments they are encountering shortages in key personnel and are concerned about the industry’s ability to absorb change and integrate new workflows with HIT,” the study states.

The Affordable Care Act, with its emphasis on accountable care organizations and health insurance exchanges, means that insurers will have to sell to patients more than they did in the past. “In many ways they are playing catch up with many other industries — such as retail — in attracting, engaging and building loyalty among consumers.”

Gary Harvey, vice president of information technology at Blue Cross Blue Shield of Michigan, told researchers that “We can easily find someone who knows a tool, how to extract data from using it, and how to technically layer the data. But it’s very difficult to find someone who can look at the data and determine whether it is the right data to answer a business question or solve a problem. We see a huge gap in the talent pool for analytics talent. And it’s even harder for us to find people with clinical expertise.”

Remember the adage about giving someone a fish as opposed to teaching him to fish? Well, it doesn’t apply here. But your thoughts do, so please do tell. What are you doing about this problem?

The author is managing editor of Managed Care.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.